InMode Announces Morpheus8 FDA 510(k) Clearance For Soft Tissue Contraction For Fractional Radiofrequency Microneedling
Portfolio Pulse from Benzinga Newsdesk
InMode Ltd. (INMD) has received FDA 510(k) clearance for its Morpheus8 device, which is used for soft tissue contraction through fractional radiofrequency microneedling.
July 17, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
InMode Ltd. has received FDA 510(k) clearance for its Morpheus8 device, which is designed for soft tissue contraction using fractional radiofrequency microneedling. This regulatory approval could enhance the company's product portfolio and market position.
The FDA 510(k) clearance is a significant regulatory milestone that allows InMode to market its Morpheus8 device for soft tissue contraction. This could lead to increased sales and market share, positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100